Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial Prospectively collected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback